Jacobs Levy Equity Management
SCPH

Jacobs Levy Equity Management’s scPharmaceuticals SCPH Stock Holding History

Jacobs Levy Equity Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-81,891
Closed -$411K – 1076
2021
Q4 		$411K Sell
81,891
-20,316
-20% -$112K ﹤0.01% 859
2021
Q3 		$680K Sell
102,207
-36,397
-26% -$217K ﹤0.01% 822
2021
Q2 		$847K Sell
138,604
-2,363
-2% -$14.3K 0.01% 773
2021
Q1 		$937K Buy
140,967
+114,803
+439% +$787K 0.01% 750
2020
Q4 		$138K Buy
+26,164
New +$205K ﹤0.01% 980
2020
Q1 		– Sell
-17,791
Closed -$101K – 1083
2019
Q4 		$101K Buy
17,791
+3,157
+22% +$16.2K ﹤0.01% 975
2019
Q3 		$86K Sell
14,634
-22,287
-60% -$126K ﹤0.01% 896
2019
Q2 		$118K Buy
36,921
+13,225
+56% +$43.3K ﹤0.01% 910
2019
Q1 		$71K Buy
+23,696
New +$81.4K ﹤0.01% 941

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Jacobs Levy Equity Management's SCPH Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of scPharmaceuticals (SCPH) in Q1 2022, closing a stake of 81,891 shares — an estimated $411K sold.

Jacobs Levy Equity Management first reported a position in SCPH in Q1 2019 and held it in 9 quarters. The position peaked at $937K in Q1 2021. 37 funds tracked by Wall St. Rank hold SCPH as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining scPharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 81,891 scPharmaceuticals shares in Q1 2022, an estimated $411K.
  • Jacobs Levy Equity Management first reported a position in scPharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Jacobs Levy Equity Management's scPharmaceuticals position peaked at $937K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.